These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21944955)

  • 1. Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study.
    Hinkelmann K; Moritz S; Botzenhardt J; Muhtz C; Wiedemann K; Kellner M; Otte C
    Psychoneuroendocrinology; 2012 May; 37(5):685-92. PubMed ID: 21944955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor stimulation improves cognitive function and decreases cortisol secretion in depressed patients and healthy individuals.
    Otte C; Wingenfeld K; Kuehl LK; Kaczmarczyk M; Richter S; Quante A; Regen F; Bajbouj M; Zimmermann-Viehoff F; Wiedemann K; Hinkelmann K
    Neuropsychopharmacology; 2015 Jan; 40(2):386-93. PubMed ID: 25035081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Guzmán D; Guàrdia-Olmos J; Hinojosa-Calvo E; Herrera-Abarca JE
    J Psychiatr Res; 2009 Jun; 43(9):855-63. PubMed ID: 19128810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA; Loft H; Olsen CK
    J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive impairment in major depression: association with salivary cortisol.
    Hinkelmann K; Moritz S; Botzenhardt J; Riedesel K; Wiedemann K; Kellner M; Otte C
    Biol Psychiatry; 2009 Nov; 66(9):879-85. PubMed ID: 19709646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder.
    Hernández ME; Mendieta D; Martínez-Fong D; Loría F; Moreno J; Estrada I; Bojalil R; Pavón L
    Eur Neuropsychopharmacol; 2008 Dec; 18(12):917-24. PubMed ID: 18805677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cortisol, moderated by age, is associated with antidepressant treatment outcome and memory improvement in Major Depressive Disorder: A retrospective analysis.
    Jain FA; Connolly CG; Reus VI; Meyerhoff DJ; Yang TT; Mellon SH; Mackin S; Hough CM; Morford A; Wolkowitz OM
    Psychoneuroendocrinology; 2019 Nov; 109():104386. PubMed ID: 31382170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
    Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
    CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
    Knorr UB
    Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response.
    Papakostas GI; Chuzi SE; Sousa JL; Fava M
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):175-80. PubMed ID: 19641981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
    J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor function in depressed patients and healthy individuals.
    Hinkelmann K; Hellmann-Regen J; Wingenfeld K; Kuehl LK; Mews M; Fleischer J; Heuser I; Otte C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():183-8. PubMed ID: 27519144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy.
    Dziurkowska E; Wesolowski M; Dziurkowski M
    Arch Womens Ment Health; 2013 Apr; 16(2):139-47. PubMed ID: 23371518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment.
    Vythilingam M; Vermetten E; Anderson GM; Luckenbaugh D; Anderson ER; Snow J; Staib LH; Charney DS; Bremner JD
    Biol Psychiatry; 2004 Jul; 56(2):101-12. PubMed ID: 15231442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of mineralocorticoid receptor blockade on empathy in patients with major depressive disorder.
    Wingenfeld K; Kuehl LK; Dziobek I; Roepke S; Otte C; Hinkelmann K
    Cogn Affect Behav Neurosci; 2016 Oct; 16(5):902-10. PubMed ID: 27383377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Otte C; Hinkelmann K; Moritz S; Yassouridis A; Jahn H; Wiedemann K; Kellner M
    J Psychiatr Res; 2010 Apr; 44(6):339-46. PubMed ID: 19909979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study.
    Rudzki L; Ostrowska L; Pawlak D; Małus A; Pawlak K; Waszkiewicz N; Szulc A
    Psychoneuroendocrinology; 2019 Feb; 100():213-222. PubMed ID: 30388595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.
    Levkovitz Y; Alpert JE; Brintz CE; Mischoulon D; Papakostas GI
    Eur Psychiatry; 2012 Oct; 27(7):518-21. PubMed ID: 21665441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of short-term use of benzodiazepines on cognitive function of major depressive disorder patients being treated with antidepressants.
    Duan Y; Wei J; Geng W; Jiang J; Zhao X; Li T; Jiang Y; Shi L; Cao J; Zhu G; Zhang K; Yu X
    J Affect Disord; 2019 Sep; 256():1-7. PubMed ID: 31154087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.